

## DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment, and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

## OVERVIEW

Genetic testing is defined by the National Human Genome Research Institute (NHGRI) as an array of techniques including analysis of human DNA, RNA, or protein. Genetic tests are used as a health care tool to detect gene variants associated with a specific disease or condition, as well as for non-clinical uses such as paternity testing and forensics. In the clinical setting, genetic tests can be performed to determine the genetic cause of a disease, confirm a suspected diagnosis, predict future illness, detect when an individual might pass a genetic mutation to his or her children, and predict response to therapy. They are also performed to screen newborns, fetuses, or embryos used in in vitro fertilization for genetic defects. (NHGRI, 2020; NHGRI, 2019).

Genetic testing includes testing used to determine a person's genotype. This can be determined for germline cells (those rising from the germ cells and relevant to the majority of the body's cells) or for certain somatic cells (acquired such as tumor cells). A genotype is a DNA blueprint linked to the clinical appearances of a trait or disease (phenotype). Genotyping can refer to the determination of a genotype or to a certain type of microarray that identifies the genotype for a subset of selected nucleotide variants. Genetic testing also has ethical, legal, and psychosocial issues. These include psychosocial consequences of testing; disclosure to family members; testing children; undisclosed familial relationships; and genetic discrimination. Protections for discrimination are covered under the Americans with Disabilities Act, the Genetic Information Nondiscrimination Act, and the Affordable Care Act. (Kohlmann & Slavotinek, 2022).

### Genetic Counseling

The National Society of Genetic Counselors defines genetic counseling as the process of aiding individuals to understand and acclimate to the medical, psychological, and familial implications of genetic contributions to disease. Genetic counseling includes the compilation of a detailed family history; interpretation of the family history with the medical history to assess the chance of disease occurrence or recurrence; patient and family education about the inheritance, testing, management, risk reduction, resources, and research regarding the individual's specific condition; and counseling to help the individual make informed choices to provide appropriate interventions. Indications for referral can include, but are not limited to, personal or family history of a confirmed clinical diagnosis with a known genetic etiology (e.g., hemophilia, neurofibromatosis, Marfan syndrome). Genetic testing may also be warranted when an individual has an increased risk due to genetic or environmental factors or uncertainty about genetic basis. (Raby & Kohlmann, 2022).

Federal regulation of genetic tests is conducted by the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and the Federal Trade Commission (NHGRI, 2020). The FDA regulates medical products and devices while the CMS Clinical Laboratory Improvement Amendments of 1988 (CLIA) provides regulation of clinical laboratories and testing services. Additional regulation exists for laboratories that develop laboratory-developed tests – this includes tests developed for use only in one laboratory. While largely federally regulated, some laboratories are also regulated at the State-level (AACC, 2021; AACC, 2020; HHS, 2008).

# Molina Clinical Policy

## Genetic Testing: Policy No. 051

Last Approval: 4/13/2023  
Next Review Due By: April 2024



### Genetic Testing Access to Test Information

The Genetic Testing Registry (GTR) provides a central location for voluntary submission of genetic test information by providers. This includes the purpose of a given test, laboratory contact information and credentials, as well as the test's methodology, validity, and evidence of usefulness. Overall, the aim of the GTR is to advance the public health and research into the genetic basis of health and disease (National Center for Biotechnology Information, n.d.).

GeneReviews are an international resource that provides clinically relevant and medically actionable information for inherited conditions. Diagnosis, management, and genetic counseling information are included. Experts on the specific condition write the individual chapters; GeneReviews contains over 800 chapters. Chapters are reviewed every four to five years or as necessary (Adam et al., 2022).

## COVERAGE POLICY

For ALL requests, Molina uses this clinical policy along with MCG criteria as an overarching policy along with specific criteria for evaluation of a specific genetic test.

The reviewer must apply *MCP-051: Genetic Testing* to **ALL** requests except for any stand-alone genetic testing clinical policies (e.g., *MCP-157: Cell Free DNA Screening for Chromosomal Aneuploidy*).

Genetic testing **is considered medically necessary and may be authorized** when the following criteria are met:

1. The genetic test is ordered by a practitioner within the scope of their practice or a medical geneticist; **AND**
2. Pre-and post- test genetic counseling must be performed by a board-certified medical geneticist, certified genetic counselor or provider; **AND**
3. Presence of documented key risk factors that suggest a genetic disorder:
  - a. Clinical features indicative of a condition or disease; **OR**
  - b. High risk of inheriting the disease based upon personal history, family history, documentation of a genetic mutation and/or ethnic background; **OR**
  - c. Following history, physical examination, pedigree analysis and completion of conventional diagnostic testing, a definitive diagnosis remains uncertain and a hereditary diagnosis is suspected.

### AND

4. Carrier or predictive testing requires documentation confirming that a causative genetic change has been identified in an affected family member;

NOTE: Genetic testing of an asymptomatic person in a family with several relatives affected with disease is considered predictive genetic testing. Targeted predictive genetic testing of individual diseases is appropriate when the specific indications for each test are met.

### AND

5. Documentation is provided that supports the validity and clinical utility of test results that will be used to significantly alter the management or treatment of the disease (e.g., surgery, the extent of surgery, a change in surveillance, hormonal manipulation, or a change from standard therapeutic or adjuvant chemotherapy);

### OR

Scientific literature providing evidence of **ALL** the following:

- a.  $\geq 2$  published studies from peer reviewed scientific journals that clearly establish the phenotype/genotype relationship of the condition; **OR**
- b.  $\geq 1$  study from a peer reviewed scientific journal on clinical validity with high accuracy that a test predicts the presence or absence of a clinical predisposition or condition (e.g., prediction of overall survival or recurrence-free survival).

### AND

## Molina Clinical Policy

### Genetic Testing: Policy No. 051

Last Approval: 4/13/2023

Next Review Due By: April 2024



- c. There is a clinically significant impact from a positive or negative test result on patient care. This includes instances where an effective treatment option, or other measurable clinical benefit is available following the test results to significantly improve health-related outcomes. Conditions with no available treatment or prevention options such as Alzheimer disease must be evaluated by a Medical Director for authorization.

#### AND

6. The clinical testing laboratory must be accredited by CLIA or a CLIA waiver is in place or accredited by the State and/or other applicable accrediting agencies.

### Continuation of Therapy

1. Testing is allowed once during the member's lifetime per disease for diagnostic purposes.
2. A second genetic test may be authorized in one of the following circumstances:
  - a. The genetic test identifies other mutations not previously tested and is different from the original test; **OR**
  - b. The genetic test measures gene expressions or identifies somatic mutations which can vary over time, when clinically appropriate.

### Limitations and Exclusions

Genetic testing **is considered not medically necessary** under the following circumstances (Nambot et al, 2018; Sawyer et al., 2016):

1. Criteria other than those outlined under the "Coverage Criteria" section above.
2. Testing for conditions or purposes where the test results would not directly influence the management or treatment of the disease or condition (e.g., disease without known treatment). Refer to the Corporate / Health Plan experimental and investigational policy as appropriate.
3. Testing for informational purposes or management of a member's family member.
4. For cases of carrier testing when there is no meaningful impact on health outcomes.
5. Minors under the age of 18 for adult-onset conditions that have no preventative or therapeutic options.
6. Population screening in individuals without a personal or family history (except for State mandated or required newborn screening or prenatal screening for certain conditions).
7. More than one lifetime test for each disease or condition except as defined above.
8. Whole Genome Sequencing (WGS).

Sources: National Society of Genetic Counselors; Adam et al., 2022; Miller et al., 2021; AMR, 2018; <sup>1-4</sup>ACOG; Hampel et al., 2015; Robson et al., 2015; AAP, 2013; Green et al., 2013; Rehm et al., 2013; Ross et al., 2013; ACMG, 2012.

**DOCUMENTATION REQUIREMENTS.** Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member.

## NATIONAL AND PROFESSIONAL ORGANIZATIONS

Please find below a listing on policy statements and committee opinions from the following national and professional organizations (links are below in the Reference section):

### **American Association for Clinical Chemistry (AACC)**

- *Modernization of CLIA: Laboratory Developed Tests*
- *Oversight of Laboratory Developed Tests*

### **American Academy of Pediatrics (AAP) & American College of Medical Genetics and Genomics (ACMG)**

- *Ethical and Policy Issues in Genetic Testing and Screening of Children*
- *Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children*

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



**American College of Medical Genetics and Genomics (ACMG)**

- *ACMG Clinical Laboratory Standards for Next-Generation Sequencing*
- *ACMG SF v3. List for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing*
- *Points to Consider in the Clinical Application of Genomic Sequencing*
- *Policy Statement: Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing*
- *A Practice Guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral Indications for Cancer Predisposition Assessment*
- *Addendum: A Practice Guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral Indications for Cancer Predisposition Assessment*

**American College of Obstetricians and Gynecologists (ACOG)**

- *Carrier Screening in the Age of Genomic Medicine (No. 690)*
- *Consumer Testing for Disease Risk (No. 816)*
- *Ethical Issues in Genetic Testing (No. 410)*
- *Personalized Genomic Testing for Disease Risk (No. 527)*

**American Society of Clinical Oncology (ASCO)**

- *Genetic and Genomic Testing for Cancer Susceptibility*

**National Society of Genetic Counselors**

- *Various Practice Guidelines*

**CODING & BILLING INFORMATION**

**CPT Codes**

CPT	Description
81161	DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed
81171	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., Fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles
81172	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., Fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (e.g., expanded size and methylation status)
81173	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence
81174	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant
81200	ASPA (aspartoacylase) (e.g., Canavan disease) gene analysis, common variants (e.g., E285A, Y231X)
81204	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (e.g., expanded size or methylation status)
81205	BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., Maple syrup urine disease) gene analysis, common variants (e.g., R183P, G278S, E422X)
81209	BLM (Bloom syndrome, RecQ helicase-like) (e.g., Bloom syndrome) gene analysis, 2281del6ins7 variant
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (e.g., acute myeloid leukemia), gene analysis, full gene sequence
81220	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; common variants (e.g., ACMG/ACOG guidelines)
81221	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; known familial variants
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; duplication/deletion variants
81223	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; full gene sequence

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>81224</b>	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; intron 8 poly-T analysis (e.g., male infertility)
<b>81225</b>	CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *8, *17)
<b>81226</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
<b>81227</b>	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *5, *6)
<b>81228</b>	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization (CGH) microarray analysis
<b>81229</b>	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis
<b>81230</b>	CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (e.g., drug metabolism) gene analysis, common variant(s) (e.g., *2, *22)
<b>81231</b>	CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (e.g., drug metabolism) gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *7)
<b>81232</b>	DPYD (dihydropyrimidine dehydrogenase) (e.g., 5-fluorouracil/5-FU and capecitabine drug metabolism) gene analysis, common variant(s) (e.g., *2A, *4, *5, *6)
<b>81240</b>	F2 (prothrombin, coagulation factor II) (e.g., hereditary hypercoagulability) gene analysis, 20210G>A variant
<b>81241</b>	F5 (coagulation Factor V) (e.g., hereditary hypercoagulability) gene analysis, Leiden variant
<b>81242</b>	FANCC (Fanconi anemia, complementation group C) (e.g., Fanconi anemia, type C) gene analysis, common variant (e.g., IVS4+4A>T)
<b>81243</b>	FMR1 (Fragile X mental retardation 1) (e.g., Fragile X mental retardation) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles
<b>81244</b>	FMR1 (Fragile X mental retardation 1) (e.g., Fragile X mental retardation) gene analysis; characterization of alleles (e.g., expanded size and promoter methylation status)
<b>81245</b>	FLT3 (FMS-related tyrosine kinase 3) (e.g., acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (i.e., exons 14, 15)
<b>81246</b>	FLT3 (FMS-related tyrosine kinase 3) (e.g., acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (e.g., D835, I836)
<b>81250</b>	G6PC (glucose-6-phosphatase, catalytic subunit) (e.g., Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (e.g., R83C, Q347X)
<b>81251</b>	GBA (glucosidase, beta, acid) (e.g., Gaucher disease) gene analysis, common variants (e.g., N370S, 84GG, L444P, IVS2+1G>A)
<b>81255</b>	HEXA (hexosaminidase A [alpha polypeptide]) (e.g., Tay-Sachs disease) gene analysis, common variants (e.g., 1278insTATC, 1421+1G>C, G269S)
<b>81256</b>	HFE (hemochromatosis) (e.g., hereditary hemochromatosis) gene analysis, common variants (e.g., C282Y, H63D)
<b>81257</b>	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g., Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant Spring)
<b>81258</b>	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant
<b>81259</b>	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence
<b>81260</b>	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (e.g., familial dysautonomia) gene analysis, common variants (e.g., 2507+6T>C, R696P)
<b>81265</b>	Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (e.g., pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [e.g., buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



81266	Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (e.g., additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure)
81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants
81277	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities
81290	MCOLN1 (mucolipin 1) (e.g., Mucopolipidosis, type IV) gene analysis, common variants (e.g., IVS3-2A>G, del6.4kb)
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (e.g., hereditary hypercoagulability) gene analysis, common variants (e.g., 677T, 1298C)
81302	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis
81303	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant
81304	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants
81310	NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, exon 12 variants
81313	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (e.g., prostate cancer)
81321	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant
81324	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
81325	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis
81326	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (e.g., adverse drug reaction) gene analysis, common variant(s) (e.g., *5)
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
81332	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (e.g., alpha-1-antitrypsin deficiency), gene analysis, common variants (e.g., *S and *Z)
81346	TYMS (thymidylate synthetase) (e.g., 5-fluorouracil/5-FU drug metabolism) gene analysis, common variant(s) (e.g., tandem repeat variant)
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
81355	VKORC1 (vitamin K epoxide reductase complex, subunit 1) (e.g., warfarin metabolism), gene analysis, common variants (e.g., -1639G>A, c.173+1000C>T)
81370	HLA Class I and II typing, low resolution (e.g., antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and DQB1
81371	HLA Class I and II typing, low resolution (e.g., antigen equivalents); HLA-A, -B, and DRB1 (e.g., verification typing)
81372	HLA Class I typing, low resolution (e.g., antigen equivalents); complete (i.e., HLA-A, -B, and C)
81373	HLA Class I typing, low resolution (e.g., antigen equivalents); 1 locus (e.g., HLA-A, -B, or C), each
81374	HLA Class I typing, low resolution (e.g., antigen equivalents); 1 antigen equivalent (e.g., B*27), each
81375	HLA Class II typing, low resolution (e.g., antigen equivalents); HLA-DRB1/3/4/5 and DQB1
81376	HLA Class II typing, low resolution (e.g., antigen equivalents); 1 locus (e.g., HLA-DRB1, DRB3/4/5, -DQB1, -DQA1, -DPB1, or DPA1), each
81377	HLA Class II typing, low resolution (e.g., antigen equivalents); 1 antigen equivalent, each

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



81378	HLA Class I and II typing, high resolution (i.e., alleles or allele groups), HLA-A, -B, -C, and DRB1
81379	HLA Class I typing, high resolution (i.e., alleles or allele groups); complete (i.e., HLA-A, -B, and C)
81380	HLA Class I typing, high resolution (i.e., alleles or allele groups); 1 locus (e.g., HLA-A, -B, or C), each
81381	HLA Class I typing, high resolution (i.e., alleles or allele groups); 1 allele or allele group (e.g., B*57:01P), each
81382	HLA Class II typing, high resolution (i.e., alleles or allele groups); 1 locus (e.g., HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1, -DQA1, -DPB1, or DPA1), each
81383	HLA Class II typing, high resolution (i.e., alleles or allele groups); 1 allele or allele group (e.g., HLA-DQB1*06:02P), each
81400	Molecular Pathology Procedure Level 1
81401	Molecular Pathology Procedure Level 2
81402	Molecular Pathology Procedure Level 3
81403	Molecular Pathology Procedure Level 4
81404	Molecular Pathology Procedure Level 5
81405	Molecular Pathology Procedure Level 6
81406	Molecular Pathology Procedure Level 7
81407	Molecular Pathology Procedure Level 8
81408	Molecular Pathology Procedure Level 9
81410	Aortic dysfunction or dilation (e.g., Marfan syndrome, Loeys Dietz syndrome, Ehler Danlossyndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK
81411	Aortic dysfunction or dilation (e.g., Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis, panel must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1
81412	Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1
81413	Cardiac ion channelopathies (e.g., Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A)
81414	Cardiac ion channelopathies (e.g., Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1
81415	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis
81416	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (e.g., parents, siblings) (List separately in addition to code for primary procedure)
81417	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (e.g., updated knowledge or unrelated condition/syndrome)
81418	Drug metabolism (e.g., pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis
81425	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis
81426	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (e.g., parents, siblings) (List separately in addition to code for primary procedure)
81427	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (e.g., updated knowledge or unrelated condition/syndrome)
81432	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, TP53

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>81433</b>	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11
<b>81435</b>	Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11
<b>81436</b>	Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); duplication/deletion analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4
<b>81437</b>	Hereditary neuroendocrine tumor disorders (e.g., medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL
<b>81438</b>	Hereditary neuroendocrine tumor disorders (e.g., medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL
<b>81439</b>	Hereditary cardiomyopathy (e.g., hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (e.g., DSG2, MYBPC3, MYH7, PKP2, TTN)
<b>81440</b>	Nuclear encoded mitochondrial genes (e.g., neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP
<b>81443</b>	Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucopolysaccharidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)
<b>81448</b>	Hereditary peripheral neuropathies panel (e.g., Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (e.g., BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, and SPTLC1)
<b>81460</b>	Whole mitochondrial genome (e.g., Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection
<b>81465</b>	Whole mitochondrial genome large deletion analysis panel (e.g., Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed
<b>81470</b>	X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2
<b>81471</b>	X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2
<b>81493</b>	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score
<b>81539</b>	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score
<b>81541</b>	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-specific mortality risk score
<b>81542</b>	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score



**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>81551</b>	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy
<b>0005U</b>	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score
<b>0008U</b>	Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next generation sequencing, formalin-fixed paraffin embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin
<b>0023U</b>	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin
<b>0029U</b>	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (i.e., CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)
<b>0030U</b>	Drug metabolism (warfarin drug response), targeted sequence analysis (i.e., CYP2C9, CYP4F2, VKORC1, rs12777823)
<b>0031U</b>	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2) (e.g., drug metabolism) gene analysis, common variants (i.e., *1F, *1K, *6, *7)
<b>0032U</b>	COMT (catechol-O-methyltransferase) (drug metabolism) gene analysis, c.472G>A (rs4680) variant
<b>0033U</b>	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (e.g., citalopram metabolism) gene analysis, common variants (i.e., HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])
<b>0036U</b>	Exome (i.e., somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses
<b>0046U</b>	FLT3 (FMS-related tyrosine kinase 3) (e.g., acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative
<b>0047U</b>	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score
<b>0049U</b>	NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, quantitative
<b>0050U</b>	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements
<b>0053U</b>	Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade
<b>0070U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, common and select rare variants (i.e., *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)
<b>0071U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)
<b>0072U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)
<b>0073U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)
<b>0074U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)
<b>0075U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., 5' gene duplication/multiplication) (List separately in addition to code for primary procedure)
<b>0076U</b>	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., 3' gene duplication/ multiplication) (List separately in addition to code for primary procedure)

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0078U</b>	Pain management (opioid-use disorder) genotyping panel, 16 common variants (i.e., ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder
<b>0094U</b>	Genome (e.g., unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis
<b>0101U</b>	Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])
<b>0102U</b>	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated [17 genes (sequencing and deletion/duplication)]
<b>0103U</b>	Hereditary ovarian cancer (e.g., hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated [24 genes (sequencing and deletion/duplication); EPCAM (deletion/duplication only)]
<b>0113U</b>	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score
<b>0129U</b>	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)
<b>0130U</b>	Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)
<b>0131U</b>	Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)
<b>0132U</b>	Hereditary ovarian cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)
<b>0133U</b>	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)
<b>0134U</b>	Hereditary pan cancer (e.g., hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)
<b>0135U</b>	Hereditary gynecological cancer (e.g., hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)
<b>0136U</b>	ATM (ataxia telangiectasia mutated) (e.g., ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0137U</b>	PALB2 (partner and localizer of BRCA2) (e.g., breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0138U</b>	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0156U</b>	Copy number (e.g., intellectual disability, dysmorphism), sequence analysis
<b>0157U</b>	APC (APC regulator of WNT signaling pathway) (e.g., familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0158U</b>	MLH1 (mutL homolog 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0159U</b>	MSH2 (mutS homolog 2) (e.g., hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0160U</b>	MSH6 (mutS homolog 6) (e.g., hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0161U</b>	PMS2 (PMS1 homolog 2, mismatch repair system component) (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)
<b>0162U</b>	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)
<b>0170U</b>	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis
<b>0171U</b>	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements, and minimal residual disease, reported as presence/absence
<b>0173U</b>	Psychiatry (i.e., depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes
<b>0175U</b>	Psychiatry (e.g., depression, anxiety); genomic analysis panel, variant analysis of 15 genes
<b>0203U</b>	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness
<b>0205U</b>	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age related macular-degeneration risk associated with zinc supplements
<b>0209U</b>	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes, and areas of homozygosity for chromosomal abnormalities
<b>0214U</b>	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification, and categorization of genetic variants, proband
<b>0215U</b>	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (e.g., parent, sibling)
<b>0218U</b>	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification, and characterization of genetic variants
<b>0235U</b>	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
<b>0237U</b>	Cardiac ion channelopathies (e.g., Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
<b>0290U</b>	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score
<b>0291U</b>	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score
<b>0292U</b>	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score
<b>0293U</b>	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score
<b>0326U</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0327U</b>	Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed
<b>0001U</b>	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported
<b>0007U</b>	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service
<b>0009U</b>	Oncology (breast cancer), ERBB2 (HER2) copy number by fish, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (dep) sorting, reported as ERBB2 gene amplified or non-amplified
<b>0016U</b>	Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation
<b>0017U</b>	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected
<b>0018U</b>	Oncology (thyroid), micro-RNA profiling by rt-PCR of 10 micro RNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy
<b>0019U</b>	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents
<b>0022U</b>	Targeted genomic sequence analysis panel, cholangiocarcinoma and non-small cell lung neoplasia, DNA and RNA analysis, 1-23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider
<b>0026U</b>	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("positive, high probability of malignancy" or "negative, low probability of malignancy")
<b>0027U</b>	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15
<b>0034U</b>	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (e.g., thiopurine metabolism) gene analysis, common variants (i.e., TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)
<b>0037U</b>	Targeted genomic sequence analysis, solid organ neoplasm, dna analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
<b>0040U</b>	BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative
<b>0045U</b>	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time rt-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score
<b>0048U</b>	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)
<b>0055U</b>	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma
<b>0060U</b>	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
<b>0069U</b>	Oncology (colorectal), micro-RNA, rt-PCR expression profiling of mir-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression sco
<b>0079U</b>	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification
<b>0084U</b>	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens
<b>0087U</b>	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score
<b>0088U</b>	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0089U</b>	Oncology (melanoma), gene expression profiling by rtqPCR, prame and linc00518, superficial collection using adhesive patch(es)
<b>0090U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by rt-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant)
<b>0105U</b>	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)
<b>0111U</b>	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue
<b>0112U</b>	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene
<b>0120U</b>	Oncology (b-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal b-cell lymphoma (PMBCL) and diffuse large b-cell lymphoma (DLBCL) with cell of origin subtyping in the latter
<b>0140U</b>	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected
<b>0141U</b>	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected
<b>0142U</b>	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected
<b>0152U</b>	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens
<b>0153U</b>	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement
<b>0154U</b>	Oncology (urothelial cancer), RNA, analysis by real-time rt-PCR of the fgfr3 (fibroblast growth factor receptor 3) gene analysis (i.e., p.r248c [c.742c>t], p.s249c [c.746c>g], p.g370c [c.1108g>t], p.y373c [c.1118a>g], fgfr3-tacc3v1, and fgfr3-tacc3v3) utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status
<b>0155U</b>	Oncology (breast cancer), DNA, pik3ca (phosphatidylinositol-4,5bisphosphate 3-kinase, catalytic subunit alpha) (e.g., breast cancer) gene analysis (i.e., p.c420r, p.e542k, p.e545a, p.e545d [g.1635g>t only], p.e545g, p.e545k, p.q546e, p.q546r, p.h1047l, p.h1047r, p.h1047y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as pik3ca gene mutation status
<b>0169U</b>	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism) gene analysis, common variants
<b>0172U</b>	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, dna repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score
<b>0177U</b>	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as pik3ca gene mutation status
<b>0179U</b>	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)
<b>0180U</b>	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons
<b>0181U</b>	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0182U</b>	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10
<b>0183U</b>	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19
<b>0184U</b>	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2
<b>0185U</b>	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4
<b>0186U</b>	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2
<b>0187U</b>	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2
<b>0188U</b>	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4
<b>0189U</b>	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2
<b>0190U</b>	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3
<b>0191U</b>	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6
<b>0192U</b>	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9
<b>0193U</b>	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26
<b>0194U</b>	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8
<b>0195U</b>	KLF1 (Kruppel-like factor 1), targeted sequencing (i.e., exon 13)
<b>0196U</b>	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3
<b>0197U</b>	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1
<b>0198U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5
<b>0199U</b>	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12
<b>0200U</b>	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3
<b>0201U</b>	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2
<b>0204U</b>	Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected
<b>0211U</b>	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association
<b>0216U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification, and categorization of genetic variants
<b>0217U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification, and categorization of genetic variants
<b>0221U</b>	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene
<b>0222U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0229U</b>	Bcat1 (branched chain amino acid transaminase 1) and ikzf1 (ikaros family zinc finger 1) (e.g., colorectal cancer) promoter methylation analysis
<b>0230U</b>	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
<b>0231U</b>	CACNA1A (calcium voltage-gated channel subunit alpha 1A) (e.g., spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions
<b>0232U</b>	CSTB (cystatin B) (e.g., progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
<b>0233U</b>	FXN (frataxin) (e.g., Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
<b>0234U</b>	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
<b>0236U</b>	SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (e.g., spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications, deletions, and mobile element insertions
<b>0238U</b>	Oncology (lynch syndrome), genomic DNA sequence analysis of mlh1, msh2, msh6, pms2, and epcam, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
<b>0239U</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations
<b>0242U</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements
<b>0244U</b>	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden, and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue
<b>0245U</b>	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage
<b>0246U</b>	Red blood cell antigen typing, DNA, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens
<b>0250U</b>	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVS [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden
<b>0252U</b>	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy
<b>0253U</b>	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (e.g., pre-receptive, receptive, post-receptive)
<b>0254U</b>	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy, per embryo tested
<b>0258U</b>	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics

**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0260U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
<b>0262U</b>	Oncology (solid tumor), gene expression profiling by real-time rt-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, NOTCH), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score
<b>0264U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
<b>0266U</b>	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes
<b>0268U</b>	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid
<b>0269U</b>	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid
<b>0270U</b>	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid
<b>0271U</b>	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid
<b>0272U</b>	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood, buccal swab, or amniotic fluid, comprehensive
<b>0273U</b>	Hematology (genetic hyperfibrinolysis, delayed bleeding), analysis of 9 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2 by next-generation sequencing, and PLAU by array comparative genomic hybridization), blood, buccal swab, or amniotic fluid
<b>0274U</b>	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood, buccal swab, or amniotic fluid
<b>0276U</b>	Hematology (inherited thrombocytopenia), genomic sequence analysis of 42 genes, blood, buccal swab, or amniotic fluid
<b>0277U</b>	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes, blood, buccal swab, or amniotic fluid
<b>0278U</b>	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal swab, or amniotic fluid
<b>0282U</b>	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes
<b>0285U</b>	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score
<b>0286U</b>	CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism) gene analysis, common variants
<b>0287U</b>	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)
<b>0288U</b>	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score
<b>0289U</b>	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score
<b>0294U</b>	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score
<b>0296U</b>	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing of at least 20 molecular features (e.g., human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy
<b>0298U</b>	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification



**Molina Clinical Policy**  
**Genetic Testing: Policy No. 051**

Last Approval: 4/13/2023  
 Next Review Due By: April 2024



<b>0301U</b>	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR);
<b>0302U</b>	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enhancement
<b>0313U</b>	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (ceacam5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (i.e., negative, low probability of neoplasia or positive, high probability of neoplasia)
<b>0314U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by rt-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant)
<b>0315U</b>	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by rt-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (i.e., class 1, class 2a, class 2b)
<b>0332U</b>	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (QPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy
<b>0333U</b>	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-I3 and oncoprotein des-gammaprothrombin (DCP), algorithm reported as normal or abnormal result
<b>0340U</b>	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate
<b>0341U</b>	Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid
<b>0355U</b>	APOL1 (apolipoprotein L1) (e.g., chronic kidney disease), risk variants (G1, G2)
<b>0356U</b>	Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
<b>0362U</b>	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes
<b>0363U</b>	Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma

**CODING DISCLAIMER.** Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

**APPROVAL HISTORY**

<b>4/13/2023</b>	Policy reviewed, clarified hierarchy of policy utilization, change in coverage requirements to allow practitioners within their scope practice and to allow two published studies (instead of three) to establish phenotype/genotypic alignment. Clarification of verbiage and coding.
<b>2/9/2022</b>	Policy reviewed; no changes to criteria; updated Overview, Summary of Medical Evidence and Reference sections.
<b>2/8/2021</b>	Policy reviewed; no criteria changes; added that Molina utilizes MCG and eviCore for genetic testing criteria.
<b>4/23/2020</b>	Policy reviewed, no changes.
<b>9/18/2019</b>	Policy reviewed, no changes.
<b>7/10/2018</b>	Policy reviewed; clinical criteria updated to remove exclusions for: whole exome sequencing (WES) and carrier testing in children < age 18 years; criteria updated to allow a MD specialist to perform pre/post genetic counseling; updated Summary of Medical Evidence and Reference sections.
<b>6/22/2017</b>	New policy.

## REFERENCES

### Government Agencies

1. Centers for Disease Control and Prevention (CDC). Genomic and precision health: Evaluating genomic tests. Updated June 24, 2022. Accessed January 30, 2023. <https://www.cdc.gov/genomics/gtesting/>.
2. Centers for Medicare and Medicaid Services (CMS). Medicare coverage database. Accessed January 30, 2023. <https://www.cms.gov/medicare-coverage-database/search.aspx>.
3. National Center for Biotechnology Information (NCBI). Genetic testing registry. Accessed January 30, 2023. <https://www.ncbi.nlm.nih.gov/gtr/>.
4. National Human Genome Research Institute. Regulation of genetic tests. Updated September 25, 2020. Accessed January 30, 2023. <https://www.genome.gov/about-genomics/policy-issues/Regulation-of-Genetic-Tests>.
5. National Human Genome Research Institute. Coverage and reimbursement of genetic tests. Published August 15, 2019. Accessed January 30, 2023. <https://www.genome.gov/about-genomics/policy-issues/Coverage-Reimbursement-of-Genetic-Tests>.

### Evidence Based Reviews and Publications

1. Adam MP, Ardinger HH, Pagon RA, et al. (eds.). GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2022. Accessed January 30, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1116/>.
2. Advanced Medical Reviews (AMR) Peer Review. Policy reviewed on April 26, 2018 by an AMR practicing, board-certified physician in the areas of Clinical Genetics and Pediatrics.
3. Kohlmann W, Slavotinek A. ccc. Genetic testing. Updated October 7, 2022. Accessed January 30, 2023. <http://www.uptodate.com>.
4. MCG. Search "genetic testing". Updated 2022. Accessed January 30, 2023.

### Peer Reviewed Publications

1. Ferreira-Gonzalez A, Teutsch S, Williams MS, Au SM, Fitzgerald KT, Miller PS, Fomous C. U.S. system of oversight of genetic testing: A response to the charge of the Secretary of Health and Human Services – report of the Secretary's Advisory Committee on Genetics, Health, and Society. *Per Med*. 2008 Sep 1;5(5):521-528. doi: 10.2217/17410541.5.5.521. PMID: 20490368. PMCID: PMC2873211.
2. Nambot S, Thevenon J, Kuentz P, Duffourd Y, Tisserant E, Bruel AL, et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: Substantial interest of prospective annual reanalysis. *Genet Med*. 2018 Jun;20(6):645-654. doi: 10.1038/gim.2017.162. PMID: 29095811.
3. Sawyer SL, Hartley T, Dymont DA, Beaulieu CL, Schwartzentruber J, Smith A, et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care. *Clin Genet*. 2016 Mar;89(3):275-84. doi: 10.1111/cge.12654. PMID: 26283276. PMCID: PMC5053223.

### National and Specialty Organizations

1. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. *Genet Med*. 2012 Aug;14(8):759-61. doi: 10.1038/gim.2012.74. PMID: 22863877.
2. American Association for Clinical Chemistry (AACC). Modernization of CLIA: Laboratory developed tests (LDTs). Published December 17, 2021. Accessed January 28, 2022. <https://www.aacc.org/advocacy-and-outreach/position-statements/2021/modernization-of-clia-ldts>.
3. American Association for Clinical Chemistry (AACC). Oversight of laboratory developed tests. Published October 1, 2020. Accessed January 30, 2023. <https://www.aacc.org/advocacy-and-outreach/position-statements/2020/oversight-of-laboratory-developed-tests>.
4. American Academy of Pediatrics Committee on Bioethics and Committee on Genetics; American College of Medical Genetics and Genomics Committee on Social, Ethical and Legal Issues. Ethical and policy issues in genetic testing and screening of children. *Pediatrics*. 2013 Mar;131(3):620-2. doi: 10.1542/peds.2012-3680. PMID: 23428972.
5. American College of Obstetricians and Gynecologists (ACOG). Consumer testing for disease risk (committee opinion no. 816). Published January 2021. Accessed January 30, 2023. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/01/consumer-testing-for-disease-risk>.
6. American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics. Carrier screening the age of genomic medicine (no. 690). Published March 2017. Reaffirmed 2023. Accessed January 30, 2023. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-in-the-age-of-genomic-medicine>.
7. American College of Obstetricians and Gynecologists (ACOG). Ethical issues in genetic testing (committee opinion no. 410). Published June 2008. Reaffirmed 2020. Accessed January 30, 2023. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2008/06/ethical-issues-in-genetic-testing>.
8. American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 527: Personalized genomic testing for disease risk. *Obstet Gynecol*. 2012 Jun;119(6):1318-9. doi: 10.1097/AOG.0b013e31825af3c6. PMID: 22617616.
9. Bashford MT, Kohlman W, Everett J, Parrott A, Pollin TI, Practice Guidelines Committee of the National Society of Genetic Counselors, Professional Practice and Guidelines Committee of the American College of Medical Genetics and Genomics. Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med*. 2019 Dec;21(12):2844. doi: 10.1038/s41436-019-0586-y. PMID: 31332281.
10. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. : A policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2013 Jul;15(7):565-74. doi: 10.1038/gim.2013.73. PMID: 23788249. PMCID: PMC3727274.
11. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee, National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. *Genet Med*. 2015 Jan;17(1):70-87. doi: 10.1038/gim.2014.147. PMID: 25394175.
12. Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. PMID: 34012068.

## Molina Clinical Policy Genetic Testing: Policy No. 051

Last Approval: 4/13/2023

Next Review Due By: April 2024



13. National Society of Genetic Counselors (NSGC). Practice guidelines. Accessed January 30, 2023. <https://www.nsgc.org/Policy-Research-and-Publications/Practice-Guidelines>.
14. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. *Genet Med*. 2013 Sep;15(9):733-47. doi: 10.1038/gim.2013.92. PMID: 23887774. PMCID: PMC4098820.
15. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. *J Clin Oncol*. 2015 Nov 1;33(31):3660-7. doi: 10.1200/JCO.2015.63.0996. PMID: 26324357.
16. Ross LF, Saal HM, David KL, Anderson RR, American Academy of Pediatrics, American College of Medical Genetics and Genomics. Technical report: Ethical and policy issues in genetic testing and screening of children. *Genet Med*. 2013 Mar;15(3):234-45. doi: 10.1038/gim.2012.176. PMID: 23429433.

### APPENDIX

***Reserved for State specific information. Information includes, but is not limited to, State contract language, Medicaid criteria and other mandated criteria.***